Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PRE vs PMI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PMI Captures Overall Composite Edge (48.4 HOLD vs 40.8 SELL), While PRE Leads 3–1 on Growth & Valuation Pillars

PMI Overall Winner 6-Pillar Tally: PRE 3 – 1 PMI (2 Tie) Matrix Metrics: PRE 3 – 6 PMI

As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Prenetics Global Limited Class A Ordinary Share (PRE) on higher Unified Composite conviction (48.4/100 HOLD vs. 40.8/100 SELL) after splitting the core matrix 6–3 (led by Options & Positioning), while PRE wins 3–1 across the 6-pillar growth and valuation breakdown. PRE trades at $10.31 (N/M Forward P/E, -32.5% operating margin) versus PMI at $6.30 (N/M Forward P/E, -248.1% operating margin).

  • Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. PRE 40.8/100 SELL) and 54.06β · 134% Vol risk profile, whereas PRE leads top-line expansion (+172.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: PRE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.2); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PRE vs PMI
PRE NASDAQ
Prenetics Global Limited Class A Ordinary Share
Laboratory Analytical Instruments
$10.31
-0.39% 1D
Market Cap $205.5M
TTM Revenue $199M
Forward P/E N/M
Beta / 30D Vol 1.66β · 141% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 25.0 Fund 45.0 Flow 55.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.9%), weak momentum, RSI 24
RSI-14: 24.2 · SMA20: $16.41 · SMA50: $19.53
PMI NYSE American Head-to-Head Winner
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62

6-Pillar Scorecard Institutional Category Breakdown (PRE 3 – 1 PMI)

Columns: Metric · PRE · PMI
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M 2.9x
PEG Ratio N/M N/M
EV / Revenue 0.7x 3.2x
2. Growth & Scale PRE
Revenue Growth (YoY) +172.2% +38.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $199M $6.3M
Market Cap $205.5M $17.1M
3. Profitability & Quality PRE
Gross Margin 58.1% 18.6%
Operating Margin -32.5% -248.1%
Net Profit Margin -32.6% 0.0%
Return on Equity (ROE) -67.8% 0.0%
4. Balance Sheet & Cash Flow PRE
Cash Generation (TTM) -$66M EBITDA -$17M
Cash Flow Margin -33.4% EBITDA Mgn N/A
Net Cash / Leverage $58M Net Cash $3.2M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PMI
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 89.5% (13th %ile) N/A (N/A)
Put/Call OI Skew 0.49x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Packaged Foods Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PRE (3) vs PMI (6)
Institutional Metric PRE PMI Criterion Row Edge
Market Capitalization
Scale
$205.5M $17.1M Larger Scale PRE
Trailing P/E Ratio
Valuation
N/M 2.9x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+172.2% +38.6% Higher Growth PRE
Operating Margin (TTM)
Profitability
-32.5% -248.1% Higher Margin PRE
Net Profit Margin
Profitability
-32.6% 0.0% Higher Margin PMI
Return on Equity (ROE)
Capital Efficiency
-67.8% 0.0% Higher ROE PMI
52-Week Range Position
Momentum
6% ($9–$27) 34% ($0–$18) Stronger Trend PMI
Beta / 30D Volatility
Risk Regime
1.66β · 141% Vol 54.06β · 134% Vol Lower Realized Risk PMI
Unified Institutional Score
Composite Signal
40.8 / 100 (SELL) 48.4 / 100 (HOLD) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$199M $6.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
58.1% 18.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M EBITDA ($58M Net Cash) -$17M ($3.2M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PMI +3.79 pp
PRE: -38.37% · PMI: -34.58%
3M Horizon PMI +145.22 pp
PRE: -48.96% · PMI: +96.26%
6M Horizon PMI +3482.02 pp
PRE: -42.69% · PMI: +3439.33%
1Y Horizon PMI +164.31 pp
PRE: -16.28% · PMI: +148.03%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period PRE Revenue PMI Revenue PRE Op. Margin PMI Op. Margin Margin Leader
Q2 '25 $50M $10M -70.0% -165.2% PRE
Q3 '25 $90M $0M -27.8% -293.8% PRE
Q4 '25 $150M $0M -35.9% -297.6% PRE
Q1 '26 $140M $0M -27.0% -392.3% PRE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PRE BREAKDOWN
59d in phase · OBV DISTRIBUTION
Current IV 89.5%
IV Percentile 13th %ile
Put/Call OI Skew 0.49x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PRE Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $205.5M market capitalization and -32.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PRE vs PMI Key Questions & Quantitative Answers

As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Prenetics Global Limited Class A Ordinary Share (PRE) on higher Unified Composite conviction (48.4/100 HOLD vs. 40.8/100 SELL) after splitting the core matrix 6–3 (led by Options & Positioning), while PRE wins 3–1 across the 6-pillar growth and valuation breakdown. PRE trades at $10.31 (N/M Forward P/E, -32.5% operating margin) versus PMI at $6.30 (N/M Forward P/E, -248.1% operating margin). Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. PRE 40.8/100 SELL) and 54.06β · 134% Vol risk profile, whereas PRE leads top-line expansion (+172.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: PRE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.2); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PRE leads the Growth & Scale pillar: PRE posts +172.2% YoY revenue growth and +0.0% YoY earnings growth on $199M TTM revenue (58.1% gross margin, -32.5% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 4-period historical trajectory (Q2 '25 to Q1 '26), PRE cumulative revenue shifted +180.0% while PMI shifted N/A. In operating R&D and SG&A reinvestment, PRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.

PRE and PMI trade at balanced relative valuation multiples. PRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-33.4% EBITDA margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PRE (-67.8% ROE) versus PMI (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PRE carries 89.5% implied volatility (13th %ile, Compressed (<25th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.66β · 141% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.